Leerink Partners analyst Faisal Khurshid has reiterated their bullish stance on GERN stock, giving a Buy rating yesterday.Invest with ...

A pathway once considered fundamental in Alzheimer’s disease is being studied intensely again, and may soon result in safer, ...

Eleven drugs are poised to reach blockbuster status, dramatically improving patient outcomes on a global scale.

From Novo Holding's purchase of Catalent to BMS's Karuna acquisition, here are 10 of the most significant M&A moments of 2024 ...

A number of first-in-disease, first-in-class and first-in-modality drugs approved last year have redefined therapeutic areas, ...

The approval validated the company’s $14bn acquisition deal for Karuna Therapeutics in which it gained rights to the candidate. BMS has not yet submitted Cobenfy to the EMA for marketing authorisation ...

Zai Lab has an exclusive license from Karuna Therapeutics, Inc., a company acquired by Bristol Myers Squibb, to develop, manufacture, and commercialize KarXT in Greater China (mainland China ...

Xanomeline/trospium chloride may help improve cognition in patients with acute schizophrenia and cognitive impairment, ...

For instance, cobenfy is the first new schizophrenia drug approved in nearly three decades. Developed by Karuna Therapeutics and later acquired by Bristol Myers Squibb, it targets the cholinergic ...

Bristol Myers Squibb plans to release initial late-stage trial data on Cobenfy in Alzheimer’s-related psychosis during the ...